09.10.26 -- In Vivo CAR T Needs More Than Better Cell Engineering

A closed, automated centrifuge system achieves consistent cell recovery and viability across leukopak donors and wash media, addressing key limitations of manual cell therapy processing.

Identify optimal conditions across chromatography media to maximize plasmid DNA recovery and remove critical impurities during large-scale biomanufacturing processes.

Modernize sterile production with robotic fill-finish technology that delivers multi-format flexibility and risk reduction for personalized medicine manufacturing and small-batch production demands.

Integrate thawing, washing, and enrichment into a single automated workflow to reliably produce high-quality CD34+ cell products from cryopreserved apheresis material.

Evolving CAR T cell therapies are raising the bar for manufacturing. Advances in cell expansion and the shift to serum-free media are redefining how scalable, future-ready processes are designed.

Evaluate surface treatments, scalability, and contamination risks to select the right adherent platform. Testing early ensures a seamless transition from benchtop to production.

ddPCR is becoming essential for biodistribution because it delivers precise, low‑copy quantification that qPCR can’t reliably match. Sponsors need partners with ddPCR depth across tissues and studies.

Risk-based systems, proactive problem-solving, and digital QMS tools drive operational excellence, deviation management, and compliance across biomanufacturing workflows.

Explore the critical aspects of GMP-grade raw materials in CGT manufacturing, including contamination control, aseptic strategies, quality systems, supply chain security, and regulatory compliance.

Gene-edited T cells targeting PD-1 and TIGIT are redefining approaches to cancer therapy. See how cell engineering and integrated genomic workflows uncover critical insights into T cell function.

Replace traditional plasmid manufacturing with cell-free enzymatic production for scalable, cost-efficient development free of bacterial backbone sequences.

Discover how scalable, cost-effective, and high-quality lentiviral vector manufacturing can accelerate both ex vivo and emerging in vivo CAR-T therapies.